OCUGEN OCGN 深 沪
交易中 04-19 11:03:04 美东时间
1.295
-0.025
-1.89%
华盛通- 最 高1.37
- 今 开1.29
- 成交量 177.63万股
- 最 低 1.275
- 昨 收 1.32
- 总市值 3.32亿
- 52周最高 2.105
- 市盈率 静 --
- 换手率 0.69%
- 52周最低 0.345
- 委 比 -13.39%
- 总股本 2.56亿
- 历史最高 18.77
- 量 比 1.35
- 振 幅 7.20%
- 历史最低 0.17
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ocugen stock jumps after $175M securities filing
Ocugen (NASDAQ:OCGN) shares climbed around 7% premarket after the biotechnology firm filed a prospectus related to a securities offering. Under this shelf registration process, the company may offer a...
04-18 18:21
Ocugen(OCGN.US)：2023年Q4财报实现营收603.6万美元，前值为0美元；每股收益为-0.04美元，前值为-0.10美元，预期值为-0.06美元。
Ocugen(OCGN.US)：2023年Q4财报实现营收603.6万美元，前值为0美元；每股收益为-0.04美元，前值为-0.10美元，预期值为-0.06美元...
04-17 06:50
Ocugen says EU backs a U.S. trial for gene therapy
Ocugen (NASDAQ:OCGN) shares traded higher on Wednesday after the company said that EU regulators agreed to a U.S.-based trial to support a marketing authorization application for the company’s gene th...
04-10 22:20
Why Ocugen Stock Is Climbing Today
Ocugen shares are trading higher Friday after the company announced it has received approval to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of its Phase 1/2 study. Ocugen said the Data and Safety Monitoring Board for the Phase 1/2 ArMaDa clinical trial for OCU410 has approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.
04-06 03:56
Ocugen advances Phase 1/2 trial for eye disease candidate
Ocugen (NASDAQ:OCGN) shares traded higher on Friday after the company said its Phase 1/2 trial for gene therapy candidate OCU410 for eye disorder geographic atrophy would advance to test a higher dose...
04-05 22:56
Why Ocugen Shares Are Popping Off
Ocugen shares are trading higher by 14% during Wednesday's session. The company provided an update on its business activities and financial status for 2023.
04-03 23:44
HC Wainwright & Co. Reiterates Buy on Ocugen, Maintains $7 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price target.
04-03 18:46
Ocugen Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
04-03 18:46
Ocugen slips as accounting errors force restatements
Ocugen (NASDAQ:OCGN) shares fell sharply on Tuesday after the gene therapy developer, with its 2023 financials, announced its plans to restate certain financials in reaction to several accounting erro...
04-02 23:19
HUT, CXAI and BDRX among pre-market losers
Losers: Acorda Therapeutics (ACOR) -76% as it files for Chapter 11 bankruptcy. Gritstone Bio (GRTS) -43% on prices $32.5M equity offering. Verve Therapeutics (VERV) -36% after pausing trial enrollment...
04-02 20:37
